Due to a high load of modelling projects, the rate of submission via the website has been reduced.
For a much higher submission rate, please use the Modelling API.

O14744 (ANM5_HUMAN) Homo sapiens (Human)

Protein arginine N-methyltransferase 5 UniProtKBInterProSTRINGInteractive Modelling

637 aa; Sequence (Fasta) ; (Isoform 2; Isoform 4; Isoform 5; Isoform 3); 9 identical sequences: Pan troglodytes: K7B5I7, K7AYQ8; Gorilla gorilla gorilla: G3R5J7; Theropithecus gelada: A0A8D2K4A5; Papio anubis: A0A096N5H2; Macaca mulatta: H9FNP7; Macaca fascicularis: G8F670; Rhinopithecus roxellana: A0A2K6NY20; Carlito syrichta: A0A1U7TTX7

Available Structures

54 Experimental Structures

DescriptionPDB IDOligo-stateRangeLigands
PRMT5 complex bound to covalent PBM inhibitor BRD6711 Heteromer
Q9BQA1;
13-637
QN4;CL;SFG;GOL;
Assess
HUMAN PRMT5:MEP50 Crystal Structure With MTA and Fragment Bound Heteromer
Q9BQA1;
13-637
MTA;UNL;GOL;
Assess
HUMAN PRMT5:MEP50 Crystal Structure With MTA and Fragment Bound Heteromer
Q9BQA1;
13-637
MTA;UNL;GOL;
Assess
HUMAN PRMT5:MEP50 Crystal Structure With MTA and Fragment Bound Heteromer
Q9BQA1;
13-637
MTA;UNL;GOL;
Assess
PRMT5/MEP50 crystal structure with MTA and phthalazinone fragment bound Heteromer
Q9BQA1;
13-637
CL;NA;EDO;81X;MTA;
Assess
Human PRMT5:MEP50 structure with Fragment (Example 18) and MTA Bound Heteromer
Q9BQA1;
13-637
MTA;JYX;GOL;
Assess
Crystal Structure of the human PRMT5:MEP50 Complex Heteromer
P62805; Q9BQA1;
13-637
0XU;
Assess
HUMAN PRMT5:MEP50 Crystal Structure With MTA and Fragment Bound Heteromer
Q9BQA1;
13-637
MTA;UNL;GOL;
Assess
PRMT5/MEP50 crystal structure with MTA and a phthalazinone inhibitor bound (compound (M)-31) Heteromer
Q9BQA1;
13-637
MTA;85E;
Assess
PRMT5/MEP50 with compound 30 bound Heteromer
Q9BQA1;
13-637
97L;MTA;
Assess
PRMT5/MEP50 crystal structure with sinefungin bound Heteromer
Q9BQA1;
13-637
SFG;
Assess
CRYSTAL STRUCTURE OF THE HUMAN PRMT5:MEP50 COMPLEX with JNJ44064146 Heteromer
Q9BQA1;
13-637
K8H;
Assess
Crystal structure of PRMT5:MEP50 with Compound 8 and sinefungin Heteromer
Q9BQA1;
13-637
SFG;5QJ; 16×GOL;
Assess
Crystal Structure of PRMT5:MEP50 in complex with MTA and H4 peptide Heteromer
P62805; Q9BQA1;
13-637
MTA;
Assess
Crystal structure of PRMT5:MEP50 with EPZ015666 and sinefungin Heteromer
Q9BQA1;
13-637
SFG;3XV;GOL;
Assess
Crystal structure of PRMT5:MEP50 with EPZ015866 and sinefungin Heteromer
Q9BQA1;
13-637
SFG;4Z2;GOL;
Assess
Crystal structure of PRMT5:MEP50 with Compound 15 and sinefungin Heteromer
Q9BQA1;
13-637
SFG;5QL;GOL;
Assess
Crystal structure of PRMT5:MEP50 with Compound 10 and SAM Heteromer
Q9BQA1;
13-637
SAM;5QK;GOL;
Assess
HUMAN PRMT5:MEP50 Crystal Structure With MTA and Fragment Bound Heteromer
Q9BQA1;
13-637
MTA;UNL;GOL;CL;
Assess
PRMT5(M420T mutant):MEP50 complexed with inhibitor PF-06855800 Heteromer
Q9BQA1;
13-637
ZR4;
Assess
PRMT5:MEP50 complexed with adenosine Heteromer
Q9BQA1;
13-637
ADN;
Assess
PRMT5:MEP50 Complexed with 5,5-Bicyclic Inhibitor Compound 34 Heteromer
Q9BQA1;
13-637
EDO;WFS;
Assess
PRMT5-MEP50 Complexed with SAM Heteromer
Q9BQA1;
13-637
15×EDO;CL;SAM;
Assess
HUMAN PRMT5:MEP50 Crystal Structure With MTA and Fragment Bound Heteromer
Q9BQA1;
13-637
MTA;GOL;UNL;
Assess
Human PRMT5:MEP50 structure with Fragment 1 and MTA Bound Heteromer
Q9BQA1;
13-637
PWL;MTA;PEG;EDO;
Assess
PRMT5:MEP50 complexed with inhibitor PF-06939999 Heteromer
Q9BQA1;
13-637
ZR1;
Assess
PRMT5/MEP50 with compound 29 bound Heteromer
Q9BQA1;
13-637
97X;MTA;
Assess
PRMT5:MEP50 Complexed with 5,5-Bicyclic Inhibitor Compound 72 Heteromer
Q9BQA1;
13-637
EDO;WFV;
Assess
PRMT5:MEP50 Complexed with 5,5-Bicyclic Inhibitor Compound 4 Heteromer
Q9BQA1;
13-637
WFM; 10×EDO;CL;PEG;
Assess
Crystal structure of PRMT5:MEP50 with Compound 9 and sinefungin Heteromer
Q9BQA1;
13-637
SFG;5QH;GOL;
Assess
CRYSTAL STRUCTURE OF THE HUMAN PRMT5:MEP50 COMPLEX with JNJ45031882 Heteromer
Q9BQA1;
13-637
K8N;
Assess
PRMT5(M420T mutant):MEP50 complexed with inhibitor PF-06939999 Heteromer
Q9BQA1;
13-637
ZR1;
Assess
PRMT5:MEP50 Complexed with Allosteric Inhibitor Compound 8 Heteromer
Q9BQA1;
13-637
QKY;EDO;GOL;
Assess
Discovery of Potent and Selective Covalent Protein Arginine Methyltransferase (PRMT5) Inhibitors Heteromer
Q9BQA1;
13-637
CUX;DMS;EDO;
Assess
PRMT5:MEP50 Complexed with Cyclonucleoside Compound 1 Heteromer
Q9BQA1;
13-637
EDO;LB3;
Assess
Human PRMT5:MEP50 structure with Fragment 3 and MTA Bound Heteromer
Q9BQA1;
13-637
PWX;MTA;
Assess
PRMT5/MEP50 crystal structure with MTA and MRTX-1719 bound Heteromer
Q9BQA1;
13-637
MTA;85K;
Assess
HUMAN PRMT5:MEP50 COMPLEX WITH MTA and Fragment 5 Bound Heteromer
Q9BQA1;
13-637
PJ0;MTA;SO4;EDO;PEG;CL;
Assess
PRMT5/MEP50 crystal structure with MTA and an achiral, class 1, non-atropisomeric inhibitor bound Heteromer
Q9BQA1;
13-637
NXF;MTA;
Assess
PRMT5:MEP50 complexed with inhibitor PF-06855800 Heteromer
Q9BQA1;
13-637
ZR4;
Assess
PRMT5/MEP50 crystal structure with MTA and a phthalazinone inhibitor bound (Compound 9) Heteromer
Q9BQA1;
13-637
MTA;84W;
Assess
Structure of PRMT5:MEP50 in complex with LLY-283, a potent and selective inhibitor of PRMT5, with a… Heteromer
Q9BQA1;
13-637
F5J;
Assess
Human PRMT5:MEP50 structure with Fragment 4 and MTA Bound Heteromer
Q9BQA1;
13-637
PUI;MTA;PEG;CL;
Assess
CRYSTAL STRUCTURE OF THE HUMAN PRMT5:MEP50 COMPLEX with JNJB44355437 Heteromer
Q9BQA1;
13-637
U6K;EPE;EDO;PEG;
Assess
Crystal structure of PRMT5:MEP50 with EPZ015666 and SAM Heteromer
Q9BQA1;
13-637
SAM;3XV;GOL;
Assess
PRMT5 bound to the PBM peptide from pICln Heteromer
P54105; Q9BQA1;
13-637
SFG;ACE;
Assess
Crystal structure of PRMT5:MEP50 with EPZ015666 and SAH Heteromer
Q9BQA1;
13-637
SAH;3XV;
Assess
Cryo-EM structure of the apo form of human PRMT5:MEP50 complex at a resolution of 3.4 angstrom Heteromer
Q9BQA1;
13-637
Assess
CryoEM structure of PRMT5 bound to covalent PBM-site inhibitor BRD-6988 Heteromer
Q9BQA1;
13-637
YJG;
Assess
Cryo-EM structures and computational analysis for enhanced potency in MTA-synergic inhibition of hu… Heteromer
Q9BQA1;
13-637
P2R;MTA;
Assess
PRMT5 bound to PBM peptide from Riok1 Heteromer
Q9BQA1; Q9BRS2;
14-637
SFG;
Assess
PRMT5:MEP50 Complexed with Allosteric Inhibitor Compound 1a Heteromer
Q9BQA1;
14-637
QL1;
Assess
Structure of the methylosome-Lsm10/11 complex Heteromer
P83369; Q61189; Q9BQA1;
14-637
ADN;
Assess
Crystal structure of the PRMT5 TIM barrel domain in complex with RioK1 peptide Heteromer
Q9BRS2;
41-290
Assess

1 SWISS-MODEL model

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
4gqb.1.Amonomer0.9213-637
100.00
Assess

4 SWISS-MODEL models built on isoform sequence

TemplateIsoformOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
Isoform 26ckc.1.Gmonomer0.9113-620
F5J;99.34
Assess
Isoform 36ckc.1.Gmonomer0.8913-576
F5J;99.29
Assess
Isoform 46ckc.1.Gmonomer0.8313-466
F5J;98.90
Assess
Isoform 54gqb.1.Amonomer0.9013-593
100.00
Assess